Patents Assigned to QURIENT, CO. LTD.
-
Patent number: 11945822Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: GrantFiled: April 11, 2019Date of Patent: April 2, 2024Assignees: QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBHInventors: Kiyean Nam, Jaeseung Kim, Yeejin Jeon, Donghoon Yu, Mooyoung Seo, Dongsik Park, Jan Eickhoff, Gunther Zischinsky
-
Patent number: 11858937Abstract: The present invention relates to pyrazolo [1,5-a][1,3,5]triazine and pyrazolo [1,5-a]pyrimidine derivatives having Formula I: and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: GrantFiled: April 11, 2019Date of Patent: January 2, 2024Assignees: QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBHInventors: Kiyean Nam, Jaeseung Kim, Yeejin Jeon, Donghoon Yu, Mooyoung Seo, Dongsik Park, Jan Eickhoff, Gunther Zischinsky, Uwe Koch
-
Patent number: 11447486Abstract: The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, —NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, —C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of —NH2, —N(R12)(V)pR13, —NH(V)p—OR14, —NHC(O)R15, and groups of formula 1a shown below, and their use in the treatment of diseases, inType: GrantFiled: July 31, 2015Date of Patent: September 20, 2022Assignees: INSTITUT PASTEUR KOREA, QURIENT CO., LTD.Inventors: Jaeseung Kim, Seohyun Ahn, Yeejin Jeon, Dongsik Park, Young-In Yang, Doohyung Lee, Saeyeon Lee, Jiye Ahn, Jeongjun Kim, Kiyean Nam, Sunhee Kang, Minjung Seo, Mooyoung Seo, Jeongjea Seo, Sung-Jun Han, Jung Hwan Kim, Sangchul Lee, Gahee Choi, Yunmi Lee
-
Patent number: 10934274Abstract: The present invention relates to novel compounds which are inhibitors of TAM (Axl, Mer and Tyro 3) and/or Met family receptor tyrosine kinases (RTKs). These compounds are suitable for the treatment of disorders associated with, accompanied by, caused by or induced by a receptor of the TAM family, in particular a hyperfunction thereof. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly immune-suppressive cancer, refractory cancer and cancer metastases.Type: GrantFiled: April 14, 2016Date of Patent: March 2, 2021Assignees: QURIENT CO., LTD., LEAD DISCOVERY CENTER GMBHInventors: Kiyean Nam, Jaeseung Kim, Seohyun Ahn, Yeejin Jeon, Doohyung Lee, Dongsik Park, Young-In Yang, SaeYeon Lee, Jeongjun Kim, Jiye Ahn, Hana Kim, Chun-won Jung, Carsten Schultz-Fademrecht
-
Patent number: 9855243Abstract: Provided herein is a zileuton cream type topical anti-inflammatory pharmaceutical composition, and more particularly, a zileuton cream type topical anti-inflammatory pharmaceutical composition capable of retaining stability at room temperature and of being applied topically to maximize medical effects while minimizing absorption to an entirety of body, thereby minimizing toxicity caused by the compound so as to be suitable to topical treatment of skin diseases caused by leukotriene.Type: GrantFiled: July 21, 2016Date of Patent: January 2, 2018Assignee: QURIENT CO., LTD.Inventors: Ki Yean Nam, Jeong Jun Kim, Sae Yeon Lee, Ji Ye Ahn, Chunwon Jung, Jaeseung Kim, Hwan Kyu Kang, Hana Kim
-
Patent number: 9655841Abstract: Provided herein is a zileuton cream type topical anti-inflammatory pharmaceutical composition, and more particularly, a zileuton cream type topical anti-inflammatory pharmaceutical composition capable of retaining stability at room temperature and of being applied topically to maximize medical effects while minimizing absorption to an entirety of body, thereby minimizing toxicity caused by the compound so as to be suitable to topical treatment of skin diseases caused by leukotriene.Type: GrantFiled: August 13, 2014Date of Patent: May 23, 2017Assignee: QURIENT CO., LTD.Inventors: Ki Yean Nam, Jeong Jun Kim, Soo Hyun Oh, Sae Yeon Lee, Ji Ye Ahn
-
Patent number: 9029389Abstract: The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C?O, C?S, OP(O)(O), P?O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C?O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.Type: GrantFiled: April 20, 2012Date of Patent: May 12, 2015Assignees: Institut Pasteur Korea, Qurient Co. LtdInventors: Zaesung No, Jaeseung Kim, Sung-Jun Han, Jung Hwan Kim, Young Sam Park, Sangchul Lee, Kiyean Nam, Jeongjun Kim, Jinhwa Lee, Sunhee Kang, Min Jung Seo, Saeyeon Lee, Gahee Choi
-
Publication number: 20140155387Abstract: The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C?O, C?S, OP(O)(O), P?O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C?O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.Type: ApplicationFiled: April 20, 2012Publication date: June 5, 2014Applicants: QURIENT, CO. LTD., INSTITUT PASTEUR KOREAInventors: Zaesung No, Jaeseung Kim, Sung-Jun Han, Jung Hwan Kim, Young Sam Park, Sangchul Lee, Kiyean Nam, Jeongjun Kim, Jinhwa Lee, Sunhee Kang, Min Jung Seo, Saeyeon Lee, Gahee Choi